Syndax Pharmaceuticals, Inc. SNDX
Set alert
At close
Pre-market · Nov 2, 5:00 AM ET
- YTD
- -35.03%
- 1 year
- -0.36%
- Open
- 14.06
- Prev close
- 14.15
- Mkt cap
- 1.21B
- Vol
- 2.54M
- Avg vol
- 1.96M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.62
- High
- 14.35
- Forward P/E
- -16.27
- Beta
- 0.42
- Short ratio
- 8.03
- Inst. own
- 126.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 17.30
- 200-d avg
- 20.27
- 1y target
- 37.27
News
2 days ago globenewswire.com
Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -
2 days ago globenewswire.com
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.…
3 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such investors are…
6 days ago zacks.com
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 days ago globenewswire.com
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will…
1 week ago defenseworld.net
Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Monday
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Syndax Pharmaceuticals to…
2 weeks ago benzinga.com
Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
2 weeks ago benzinga.com
Crude Oil Edges Higher; Citigroup Earnings Top Views
U.S. stocks edged lower; Citi beat Q3 estimates. Bumble and BIO-key surged, while Pershing Square, Cipher Digital and Syndax fell.
2 weeks ago benzinga.com
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.
2 weeks ago benzinga.com
Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
UnitedHealth rose after Q3 earnings and sales beat estimates; BIO-Key led gainers, while HUB Cyber Security topped premarket losers.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…